Home / CAD / FDA OKs rivaroxaban for CV event reduction in patients with CAD, PAD

FDA OKs rivaroxaban for CV event reduction in patients with CAD, PAD

The FDA has approved rivaroxaban to reduce the risk of major cardiovascular events including stroke, myocardial infarction and cardiovascular death for people with chronic peripheral or coronary arter…
Read Full Story at source (may require registration)